 |
Jerusalem, Israel, March 26, 2003
Teva and Schering-Plough Enter into License Agreement Covering Schering-Plough’s Ribavirin Patents
|
|
Jerusalem, Israel, March 26, 2003
Teva & Lundbeck Announce Successful Completion of Rasagiline Phase III Clinical Program in Parkinson’s Disease
|
|
Jerusalem, Israel, March 26, 2003
Teva Announces Tentative Approval of Metformin HCl Extended-Release Tablets
|
|
Jerusalem, Israel, February 21, 2003
Teva Announces Final Approval of Tamoxifen Citrate Tablets
|
|
Jerusalem, Israel, February 18, 2003
Teva Reports Record Sales and Earnings 2002 Sales Exceed $ 2.5 Billion Full Year EPS of $1.52, Up 43% Increase of 50% in Dividend for Q4, 2002
|
|
Jerusalem, Israel, January 27, 2003
Teva to Report Fourth Quarter 2002 Financial Results on February 18, 2003;
|
|
Jerusalem, Israel, January 27, 2003
Teva to Present at U.S. Bancorp Piper Jaffray Health Care Conference
|
|
Jerusalem, Israel, January 24, 2003
Teva Announces Final Approval of Mirtazapine 15mg, 30mg 180-day Marketing Exclusivity
|
|
Jerusalem, Israel, January 21, 2003
Teva Announces U.K. High Court Revokes Two Fosamax ® Patents
|
|
Jerusalem, Israel, January 15, 2003
Teva Announces Tentative Approval of Carboplatin Injection
|
|
Jerusalem, Israel, January 14, 2003
Teva Clarifies Media Reports Regarding Rasagiline Status
|
|
Jerusalem, Israel, January 6, 2003
Teva & Lundbeck Announce Phase III Trials Did Not Demonstrate Etilevodopa Superiority Over Standard Levodopa
|
|
Jerusalem, Israel, December 30, 2002
Teva Announces Tentative Approval of Alendronate Sodium Tablets
|
|
Jerusalem, Israel, December 18, 2002
Teva Announces the Grant of Summary Judgement for Mirtazapine Tablets, Generic Version of Remeron
|
|
Jerusalem, Israel, December 6, 2002
Teva Shares Now Trading Ex-dividend
|
|
Jerusalem, Israel, December 5, 2002
Teva Announces Approval of Amoxicillin for Oral Suspension
|
|
Jerusalem, Israel, November 27, 2002
Teva Announces Approval of Pergolide Mesylate Tablets
|
|
Jerusalem, Israel, November 26, 2002
Teva Confirms Exercise of Option Under Collaboration with Impax Laboratories, Inc.
|
|
Jerusalem, Israel, November 25, 2002
Teva Pharmaceutical Industries Ltd Announces a Two for One Stock Split
|
|
Jerusalem, Israel, November 21, 2002
Teva Announces Potential Neuroprotection Properties of Copaxone® discovered by Researchers
|
|
Jerusalem, Israel, November 18, 2002
Teva Announces Closing of $450 Million Convertible Debenture Offering
|
|
Jerusalem, Israel, November 13, 2002
Teva Announces Pricing of $375 Million Convertible Debenture Offering
|
|
Jerusalem, Israel, November 13, 2002
Teva Announces Offering of Convertible Debentures
|
|
Jerusalem, Israel, November 7, 2002
Teva to Terminate the Promise Trial Following Unfavorable Interim Analysis
|
|
Jerusalem, Israel, November 5, 2002
Teva Intends to Appeal Court Ruling on Fosamax®
|
|
Jerusalem, Israel, November 1, 2002
Teva to Join Nasdaq-100 Index
|
|
Jerusalem, Israel, October 30, 2002
Teva Announces Approval of 500mg/125mg Strength of Generic Version of Augmentin®
|
|
Jerusalem, Israel, October 30, 2002
Teva Provides Updated Outlook on 4th Quarter 2002 Earnings in Light of Amox/Clav ANDA Approval
|
|
Jerusalem, Israel, October 30, 2002
Teva Announces Approval of Generic Version of Augmentin®
|
|
Jerusalem, Israel, October 29, 2002
Teva Reports Record Third Quarter 2002 Results
|
|
Jerusalem, Israel, October 22, 2002
Teva Announces That Early Treatment of MS with Copaxone® delays Accumulation of Additional Brain Lesions
|
|
Jerusalem, Israel, October 18, 2002
Teva Announces Time Change for Third Quarter 2002 Earnings Conference Call
|
|
Jerusalem, Israel, October 16, 2002
Copaxone® Approved for Seven Days Room Temperature Storage in 16 European Countries
|
|
Jerusalem, Israel, September 12, 2002
Teva Announces Final Approval of Nizatidine Capsules
|
|
Jerusalem, Israel, September 12, 2002
Judge Grants Teva Summary Judgment of Invalidity for Patent Related to Hydrocodone Bitartrate and Ibuprofen Tablets
|
|
Jerusalem, Israel, September 5, 2002
Teva Announces Approval of Cefaclor ER Tablets
|
|
Jerusalem, Israel, September 4, 2002
Teva Announces Approval of Fenofibrate Capsules
(micronized), 67mg.
will Have 180 Days of Marketing Exclusivity
|
|
Jerusalem, Israel, August 19, 2002
Teva Announces Final Approval for Nifedipine ER 90mg Tablets
|
|
Jerusalem, Israel, August 16, 2002
Teva Comments on Court Affirmation of Relafen® Patent Challenge
|
|
Jerusalem, Israel, July 29, 2002
Teva Reports Record Second Quarter 2002 Results
|
|
Jerusalem, Israel, July 22, 2002
Teva Announces Approvable Status of Gabapentin Capsules
|
|
Jerusalem, Israel, July 15, 2002
Teva to Report Q2 Results July 29, 2002 Conference Call Scheduled for 10:00 am EST
|
|
Jerusalem, Israel, July 3, 2002
Teva Announces Approval of Tizanidine HCl Tablets
|
|
Jerusalem, Israel, July 1, 2002
Teva Announces Approval of Lisinopril Tablets and Lisinopril HCTZ Tablets
|
|
Jerusalem, Israel, July 1, 2002
Teva Closes Acquisition of Bayer's French Generic Operations
|
|
Jerusalem, Israel, June 25, 2002
Teva Closes Acquisition of Honeywell Pharmaceutical Fine Chemicals S.r.l in Italy
|
|
Jerusalem, Israel, June 20, 2002
Teva Announces Approval of Tramadol HCl Tablets
|
|
Jerusalem, Israel, May 23, 2002
Teva Announces Federal Judge Invalidates Remaining Augmentin Patents
|
|
Jerusalem, Israel, May 21, 2002
Teva Announces Agreement to Acquire Honeywell Pharmaceutical Fine Chemicals S.r.l in Italy
|
|
Jerusalem, Israel,, May 20, 2002
Copaxone® Now Available in Canada in a Pre-Filled, Ready-To-Use-Syringe
|
|
Jerusalem, Israel, May 20, 2002
Teva Announces Tentative FDA Approval for Pravastatin Tablets
|
|
Jerusalem, Israel, May 15, 2002
Teva Announces FDA Approval of Torsemide Tablets
|
|
Jerusalem, Israel, April 23, 2002
Copaxone® Now Available In The U.S. In A Pre-Filled, Ready-To-Use Syringe
|
|
Jerusalem, Israel, April 15, 2002
Teva to Announce Q1 Results on April 29, 2002
|
|
Jerusalem, Israel, April 10, 2002
Teva Announces Approval of Fenofibrate Capsules
|
|
Jerusalem, Israel, April 4, 2002
Teva Announces Agreement to Acquire Bayer France Generic Operations
|
|
Jerusalem, Israel, March 21, 2002
Teva Announces Resolution of Patent Litigation for Fenofibrate Capsules
|
|
Jerusalem, Israel, March 13, 2002
Teva Announces Federal Judge Invalidates Augmentin Patents
|
|
Jerusalem, Israel, February 28, 2002
Teva Announces Final Approval of Buspirone Tablets
|
|
Jerusalem, Israel, February 14, 2002
Israel Makov Appointed Teva’s Next President and CEO
|
|
Jerusalem, Israel, February 14, 2002
Teva Reports Record 2001 Q4 Sales of $ 567 Million; Over $ 2 Billion Sales for 2001
Earnings per ADR for Q4 (Before One-Time Charges) of $0.66
|
|
Jerusalem, Israel, February 11, 2002
Teva Announces Tentative Approval for Quinapril HCl Tablets
|
|
Jerusalem, Israel, February 6, 2002
Teva to Announce Fourth Quarter and Full Year 2001 Financial Results on February 14th, 2002
|
|
Jerusalem, Israel, February 5, 2002
Copaxone® Becomes Available to U.K. MS Patients under NHS Scheme
|
|
Jerusalem, Israel, February 5, 2002
Teva Makes Offer to Acquire French Generic Operations from Bayer
|
|
Jerusalem, Israel, January 29, 2002
Teva Announces Final Approval for Fluoxetine 10, 20 & 40 mg Capsules
|
|
Jerusalem, Israel, January 25, 2002
Teva Announces Final Approval of Metformin Tablets
|
|
Jerusalem, Israel, January 17, 2002
Teva Announces Approvable Status of ANDA for Tramadol HCl Tablets
|
|
Jerusalem, Israel, January 16, 2002
Teva Announces Tentative Approval of Mirtazapine 15mg, 30mg and 45mg
|
|
Jerusalem, Israel, January 2, 2002
Teva Announces Tentative Approval for Ciprofloxacin
|
